icon3

Alpha- 1 Antitrypsin Market By Treatment Type (Augmentation Therapy, Bronchodilators, Others) By Application (Hospitals, Specialty Clinics, Others) By Route of Administration (Parenteral, and Inhalation) Regional Analysis & Forecast to 2026

  • OI-71
  • |
  • Published date: Mar, 2019
  • |
  • Biopharmaceuticals
  • |
  • Pages

Alpha-1 antitrypsin is a member of the serine proteinase inhibitor (serpin) proteins with a broad spectrum of biological functions such as inhibition of proteases, the transport of hormones, and immune modulatory functions. Serpins are mainly expressed extracellularly, with some of them being expressed intracellularly (e.g., ov-serpins or clade B serpins). There is a wide variation in the tissue expression of serpins, which is controlled by the complex interaction of promoter and regulatory elements in the DNA sequence with transcription factors. Disorders of this protein include alpha-1 antitrypsin deficiency, in which a deficiency of alpha-1 antitrypsin leads to a chronic uninhibited tissue breakdown. This causes the degradation especially of lung tissue and eventually leads to characteristic manifestations of pulmonary emphysema.


Market Overview


The products in this market include those used for the treatment of alpha-1 antitrypsin deficiency commonly known as emphysema. It is predicted that many new biotechnology companies will move into the alpha-1 antitrypsin deficiency treatment market, and are going to work towards developing personalized medicines for genetically inherited disorders. They are also likely to invest extensively in R&D for coming up with novel treatment processes and for the development of stem cell based therapeutics. One of the major challenges affecting this market is the high cost of drugs. The high cost of alpha-1 antitrypsin therapies is responsible for impeding market growth. The manufacture of plasma proteins is expensive and account almost four times the cost of manufacturing pharmaceutical drugs.


A key factor that is driving the market growth is to improve the diagnosis of Alpha-1 antitrypsin deficiency (AATD). Detection is a crucial step in treating any disease or deficiency. Anyway, AATD stood difficult to diagnose in almost most of the cases. Based on the Alpha-1 foundation, about 3% of all the patients detected with chronic obstructive pulmonary disease (COPD) may be having undetected AATD. To overcome this, in the last few years several awareness programs were conducted to recognize and differentiate AATD from other diseases around the world. The rising patient assistance programs are one of the key emerging trends in the global Alpha-1 antitrypsin market that are sponsored by doctors, patient, drug companies, and civic groups. These programs help uninsured patients from low-income groups to get free or brand name medications at low prices.


Key Developments



  • Alpha-1 foundation oxygen travel fund is one of the programs that supply oxygen and equipment for individuals lacking the financial resources to visit their physicians, hospitals, and Alpha-1 educational events. AlphaKit QuickScreen has been developed by Grifols, a diagnostic kit that aids in quick identification of the mutated Z gene.

  • On February 28th, 2019, the Alpha-1 Foundation proudly wore its stripes to support the National Institutes of Health (NIH) sponsored Rare Disease Day (RDD) along with patient organizations, politicians, caregivers, medical professionals, researchers and industry – together to raise awareness of rare diseases, including Alpha-1 Antitrypsin Deficiency (Alpha-1).  


Segmentation


The global Alpha-1 antitrypsin drugs market is segmented as follows


By Route of Administration: Parenteral and inhalation


By Treatment Type: Augmentation Therapy, Bronchodilators, Corticosteroids, and Oxygen Therapy.


By Applications: Hospitals, Specialty Clinics, and Pharmacies.


By Regions: North America (USA, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Columbia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa).


Based on the treatment type, the augmentation therapy segment has been leading one, with the bronchodilator treatment segment standing in the second place. Based on the end user, the hospital segment stood as the leading one, and the parenteral segment has appeared as the most popular route of administration. Based on geography, North America has been leading in the treatment market, because of the rise in diagnosis rate, an increase in the prevalence of alpha-1 antitrypsin deficiency, and high healthcare expenditure.


Some of the leading companies in the market include Teva Pharmaceutical Industries Ltd., Baxter, Boehringer Ingelheim GmbH, Pfizer Inc., Kamada Ltd., AstraZeneca, Grifols S.A., LFB Biomedicaments S.A., Plc., and CSL Behring LLC.

Report Description: The report covers in-depth analysis on Alpha-1 antitrypsin Market. The report assesses the Alpha-1 antitrypsin products pipeline by stage of development (early development, pre-clinical, clinical and in approval), by application (Metabolic disorders, hematological disorders, immunologic disorders, cancer, and others). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.


The report includes in-depth company profiles of key players in Alpha-1 antitrypsin Market. The company profile includes key information on overview, financial highlights, product portfolio, business strategies, and key recent developments.


The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.


Scope:



  • Provides detailed analysis of the market structure along with forecast of the various segments and sub-segments of the Alpha-1 antitrypsin

  • Provides a comparative analysis of key marketed products and pipeline Alpha-1 antitrypsin products.

  • Provides key information on players involved on the Alpha-1 antitrypsin

  • Provides a complete overview of market segments and the regional outlook of Alpha-1 antitrypsin

  • Provides in-depth coverage of key news related toAlpha-1 antitrypsin Market, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates

Our research works on a holistic 360° approach to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involve the following steps:




  • Data Collation (Primary & Secondary)




  • In-house Estimation (Based on proprietary databases and Models)




  • Market Triangulation




  • Forecasting




  • Market-related information is assembled from both primary and secondary sources. 






  • Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services. 






  • Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others. 






  • Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. 





 


REPORT YOU MIGHT BE INTERESTED

Choose Licence Type

$3,850.00
$4,950.00


(For Corporate Licence Only) Complementary
Credit card Logo
Inquiry Before Buying

Related Reports


Contact Us

Email Us at: sales@optimainsights.org | Reach Us at: +91 966 6620 365 | +1 424 2554 365 (US)